Recent Insider Transactions • May 20
Independent Director recently sold €278k worth of stock On the 11th of May, Paul Wotton sold around 10k shares on-market at roughly €27.79 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €440k more than they bought in the last 12 months. Duyuru • May 09
Vericel Corporation Raised Revenue Guidance for the Year 2026 Vericel Corporation raised revenue guidance for the year 2026. For the period, the company expects Total revenue of $326 to $336 million, compared to previous guidance of $316 to $326 million. Duyuru • Apr 23
Vericel Corporation to Report Q1, 2026 Results on May 07, 2026 Vericel Corporation announced that they will report Q1, 2026 results Pre-Market on May 07, 2026 Duyuru • Mar 20
Vericel Corporation, Annual General Meeting, Apr 29, 2026 Vericel Corporation, Annual General Meeting, Apr 29, 2026. Duyuru • Mar 05
Vericel Corporation Announces FDA Approval For Maci Commercial Manufacturing At Burlington Facility Vericel Corporation announced that the U.S. Food and Drug Administration (FDA) has granted approval for MACI (autologous cultured chondrocytes on porcine collagen membrane) commercial manufacturing at its cell therapy manufacturing facility in Burlington, Massachusetts. The approval enables Vericel to begin commercial production of MACI at its new facility in the second quarter of 2026, positioning the Company to expand capacity to meet increasing demand for its restorative cartilage repair product and potentially commercialize MACI outside of the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Duyuru • Feb 26
Vericel Corporation Provides Earnings Guidance for the Year 2026 Vericel Corporation provided earnings guidance for the year 2026. For the period, the company expects Total net revenue of $316 to $326 million. Duyuru • Feb 12
Vericel Corporation to Report Q4, 2025 Results on Feb 26, 2026 Vericel Corporation announced that they will report Q4, 2025 results Pre-Market on Feb 26, 2026 Duyuru • Jan 13
Vericel Corporation Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2025 Vericel Corporation provided preliminary unaudited earnings guidance for the fourth quarter and full year of 2025. For the quarter, the company expects total revenue and MACI revenue growth of 23%.
For the year, the company expects total net revenue to be approximately $276 million. GAAP net income profitability expected for the second consecutive year. Board Change • Dec 30
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 8 highly experienced directors. Independent Director Lisa Wright was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Duyuru • Nov 06
Vericel Corporation Provides Revenue Guidance for the Year 2025 Vericel Corporation provided revenue guidance for the year 2025. For the period, the company expects total full-year revenue guidance of $272 million to $276 million. Duyuru • Oct 23
Vericel Corporation to Report Q3, 2025 Results on Nov 06, 2025 Vericel Corporation announced that they will report Q3, 2025 results on Nov 06, 2025 Duyuru • Jul 31
Vericel Corporation Reaffirms Earnings Guidance for the Year 2025 Vericel Corporation reaffirmed earnings guidance for the year 2025. For the period, the company expects reaffirmed MACI full-year revenue growth in the low 20% range. Updated Burn Carerevenue guidance for the second half of 2025 to be in line with recent run rate of approximately $10 million per quarter and Reaffirmed full-year profitability guidance of gross margin of 74%. Duyuru • Jul 17
Vericel Corporation to Report Q2, 2025 Results on Jul 31, 2025 Vericel Corporation announced that they will report Q2, 2025 results on Jul 31, 2025 Duyuru • May 08
Vericel Corporation Provides Revenue Guidance for the Second Quarter of 2025 and Reaffirms Earnings Guidance for the Year 2025 Vericel Corporation provided revenue guidance for the second quarter of 2025 and reaffirmed earnings guidance for the year 2025. For the second quarter, the company expects total revenue growth to be 22% to 25%.
The company reaffirmed full-year total revenue guidance with revenue growth expected to be 20% to 23%. Duyuru • Apr 24
Vericel Corporation to Report Q1, 2025 Results on May 08, 2025 Vericel Corporation announced that they will report Q1, 2025 results on May 08, 2025 Duyuru • Mar 21
Vericel Corporation, Annual General Meeting, Apr 30, 2025 Vericel Corporation, Annual General Meeting, Apr 30, 2025. Duyuru • Feb 28
Vericel Corporation Provides Earnings Guidance for the Year 2025 Vericel Corporation provided earnings guidance for the year 2025. For the period, Company expects Total net revenue growth expected to be 20% to 23%. Duyuru • Feb 13
Vericel Corporation to Report Q4, 2024 Results on Feb 27, 2025 Vericel Corporation announced that they will report Q4, 2024 results on Feb 27, 2025 Duyuru • Jan 15
Vericel Corporation Provides Financial Guidance for the Fourth Quarter and Year Ended December 31, 2024 and for the Full-Year 2025 Vericel Corporation provided financial guidance for the fourth quarter and year ended December 31, 2024 and for the full-year 2025. For the quarter, total net revenue expected to be approximately $75.2 million to $75.7 million and GAAP Net Income expected to be approximately $17.5 to $18.5 million.
For the full year 2024, total net revenue expected to be approximately $237 to $237.5 million, representing 20% growth and Achieved Full-Year GAAP Net Income profitability.
For the full year 2025, total net revenue growth expected to be 20% to 23%. New Risk • Nov 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (3.4% increase in shares outstanding). Reported Earnings • Nov 08
Third quarter 2024 earnings released: US$0.018 loss per share (vs US$0.077 loss in 3Q 2023) Third quarter 2024 results: US$0.018 loss per share (improved from US$0.077 loss in 3Q 2023). Revenue: US$57.9m (up 27% from 3Q 2023). Net loss: US$901.0k (loss narrowed 75% from 3Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Duyuru • Nov 08
Vericel Corporation Maintains Revenue Guidance for the Year 2024 Vericel Corporation maintained revenue guidance for the year 2024. For the period, the company maintained total net revenue guidance of $238 million to $242 million, or 20% to 23% growth. Duyuru • Oct 24
Vericel Corporation to Report Q3, 2024 Results on Nov 07, 2024 Vericel Corporation announced that they will report Q3, 2024 results on Nov 07, 2024 Buy Or Sell Opportunity • Oct 08
Now 22% overvalued Over the last 90 days, the stock has fallen 9.3% to €39.00. The fair value is estimated to be €31.94, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 22% per annum. Earnings are also forecast to grow by 52% per annum over the same time period. Duyuru • Aug 26
Vericel Corporation Announces FDA Approval and Commercial Availability of MACI Arthro Vericel Corporation announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) expanding the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label to include arthroscopic delivery of MACI to repair symptomatic single or multiple full-thickness cartilage defects of the knee up to 4 cm2 in size. MACI ArthroTM provides a less invasive technique compared to the current approach, allowing surgeons to evaluate and prepare the defect site as well as deliver the MACI implant through small incisions using custom-designed MACI Arthro instruments. MACI is the first FDA-approved cellularized scaffold product that applies tissue engineering processes to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. MACI is the only restorative biologic cartilage repair product approved for arthroscopic administration. MACI Arthro incorporates the advantages of an arthroscopic approach with the long-term durability and established clinical results of MACI. The custom MACI Arthro instruments are designed to treat the most common defects in the MACI addressable market, which are 2-4cm2 defects on the femoral condyles, representing approximately 20,000 patients per year or one-third of the $3 billion addressable market for MACI. In conjunction with the launch of MACI Arthro, Vericel is expanding its target surgeon base from 5,000 to 7,000 to include surgeons that perform high volumes of cartilage repair surgeries, predominantly through arthroscopic procedures. Duyuru • Aug 16
Vericel Corporation Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns Vericel Corporation announced that the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for NexoBrid®? (anacaulase-bcdb) for eschar removal in pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The FDA approval of the pediatric indication for NexoB Brid is based on the results of a global Phase 3 clinical trial, Children Innovation Debridement Study (CIDS), which evaluated the safety and efficacy of NexoBrid in hospitalized pediatric patients, as well as additional pediatric data available from Phase 3 and Phase 2 studies conducted during the clinical development of NexoBrid. Vericel is expanding its target customer base to include the approximately 20 pediatric burn centers in the United States, which the Company expects will have a meaningful impact on overall NexoBrid uptake over time. NexoBrid was initially approved for eschar removal in adults with deep partial-thickity and/or full-thrickness thermal burns by the FDA on December 28, 2022, and is commercially available in the United States. Reported Earnings • Aug 02
Second quarter 2024 earnings released: US$0.096 loss per share (vs US$0.11 loss in 2Q 2023) Second quarter 2024 results: US$0.096 loss per share (improved from US$0.11 loss in 2Q 2023). Revenue: US$52.7m (up 15% from 2Q 2023). Net loss: US$4.68m (loss narrowed 6.7% from 2Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Duyuru • Aug 02
Vericel Corporation Reaffirms Revenue Guidance for the Year 2024 Vericel Corporation reaffirms revenue guidance for the year 2024. For the period, the company Reaffirmed total net revenue guidance of $238 to $242 million, or 20% to 23% growth. Duyuru • Jul 22
Vericel Corporation Announces Executive Changes Vericel Corporation announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel’s Head of Human Resources since September 2010. Ms. Mahoney joins Vericel with more than 20 years of experience across the life sciences and medical device sectors, most recently serving as Chief Human Resources Officer at Abiomed, a global medical device company that was acquired by Johnson & Johnson in December 2022. At Abiomed, Ms. Mahoney led all aspects of HR strategy and operations, driving talent selection, leadership development and contributing to strong business performance across the company. Following the acquisition, Ms. Mahoney served as a key member of the integration team overseeing the transition of all HR-related programs into Johnson & Johnson. Prior to Abiomed, Ms. Mahoney held roles of increasing responsibility at PerkinElmer, culminating with her position as Global Talent Leader. Ms. Mahoney earned a B.A. in Marketing from Assumption College and her M.B. A from Suffolk University. Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 9 highly experienced directors. Independent Director Lisa Wright was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Duyuru • May 09
Vericel Corporation Provides Earnings Guidance for the Year 2024 Vericel Corporation provides earnings guidance for the year 2024. For the period net revenue for 2024 now expected to be in the range of $238 to $242 million, compared to the previous guidance of $237 to $241 million. Reported Earnings • May 09
First quarter 2024 earnings released: US$0.08 loss per share (vs US$0.16 loss in 1Q 2023) First quarter 2024 results: US$0.08 loss per share (improved from US$0.16 loss in 1Q 2023). Revenue: US$51.3m (up 25% from 1Q 2023). Net loss: US$3.86m (loss narrowed 49% from 1Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Duyuru • Apr 26
Vericel Corporation to Report Q1, 2024 Results on May 08, 2024 Vericel Corporation announced that they will report Q1, 2024 results on May 08, 2024 Duyuru • Mar 22
Vericel Corporation, Annual General Meeting, May 01, 2024 Vericel Corporation, Annual General Meeting, May 01, 2024, at 09:00 US Eastern Standard Time. Agenda: To consider Election of Directors Nominees; to approve, on an advisory basis, the compensation of Vericel Corporations named executive officers; to approve, on an advisory basis, the frequency of future named executive officer compensation advisory votes; and to ratify the appointment of PricewaterhouseCoopers LLP as Vericel Corporations independent registered public accounting firm for the fiscal year ending December 31, 2024. Recent Insider Transactions • Mar 12
Senior VP recently sold €336k worth of stock On the 8th of March, Sean Flynn sold around 8k shares on-market at roughly €41.41 per share. This transaction amounted to 98% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €644k more than they bought in the last 12 months. Reported Earnings • Mar 01
Full year 2023 earnings released: US$0.067 loss per share (vs US$0.35 loss in FY 2022) Full year 2023 results: US$0.067 loss per share (improved from US$0.35 loss in FY 2022). Revenue: US$197.5m (up 20% from FY 2022). Net loss: US$3.18m (loss narrowed 81% from FY 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Duyuru • Feb 29
Vericel Corporation Provides Earnings Guidance for the Fiscal Year 2024 Vericel Corporation provided earnings guidance for the fiscal year 2024. for the year, the company expects Total net revenue to be in the range of $237 million to $241 million. Duyuru • Feb 16
Vericel Corporation to Report Q4, 2023 Results on Feb 29, 2024 Vericel Corporation announced that they will report Q4, 2023 results on Feb 29, 2024 Duyuru • Jan 11
Vericel Corporation Provides Earnings Guidance for the Year 2024 Vericel Corporation provided earnings guidance for the year 2024. For the year, the company expected total revenue growth to continue to be strong in the 20% plus range, GAAP net income profitable in 2024 on track for that. Duyuru • Jan 09
Vericel Corporation Provides Earnings Guidance for the Fourth Quarter and Full-Year 2023 Vericel Corporation provided earnings guidance for the fourth quarter and Full-Year 2023. For the quarter, company expects Total net revenue to be approximately $65.0 million, representing 23% growth.For the year, company expects total net revenue to be approximately $197.5 million, representing 20% growth. Reported Earnings • Nov 09
Third quarter 2023 earnings released: US$0.077 loss per share (vs US$0.14 loss in 3Q 2022) Third quarter 2023 results: US$0.077 loss per share (improved from US$0.14 loss in 3Q 2022). Revenue: US$45.6m (up 18% from 3Q 2022). Net loss: US$3.66m (loss narrowed 44% from 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. Duyuru • Nov 09
Vericel Corporation Provides Total Net Revenue Guidance for 2023 Vericel Corporation provided Total net revenue guidance for 2023. For the period, company now expected to be in the range of $192.5 million to $197.5 million, compared to the previous guidance of $190 million to $197 million. Duyuru • Oct 26
Vericel Corporation to Report Q3, 2023 Results on Nov 08, 2023 Vericel Corporation announced that they will report Q3, 2023 results on Nov 08, 2023 New Risk • Oct 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Duyuru • Sep 21
Vericel Corporation Announces U.S. Commercial Availability of NexoBrid (Anacaulase-Bbb) for the Treatment of Severe Thermal Burns in Adults Vericel Corporation announced the U.S. commercial availability of NexoBrid®? (anacaulase-bcdb) for the removal of eschar in adults with deep partial- and/or full-thickness thermal burns. Eschar removal is a critical first step in the treatment of burns as it can reduce inflammation, stop burn progression, as well as mitigate infections and sepsis. Surgical excision, which is the current standard of care for eschar removal, often results in the removal of viable tissue. NexoBrid selectively targets eschar while preserving viable tissue, enabling more rapid and precise eschar removal, which may reduce the need for subsequent skin grafting and lessen patient trauma. Each year, approximately 40,000 people are hospitalized in the U.S. for burn-related injuries, and of those patients, more than 30,000 of them require some level of eschar removal, representing a $300 million addressable market for NexoBrid. NexoBrid can be applied in up to two applications of four hours each. A first application of NexoBrid may be applied to an area of up to 15% body surface area. A second application of NexoBrid may be applied 24 hours later, with a total treated area for both applications of up to 20% Total Body Surface Area (TBSA). Reported Earnings • Aug 03
Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2022) Second quarter 2023 results: US$0.11 loss per share (improved from US$0.19 loss in 2Q 2022). Revenue: US$45.9m (up 24% from 2Q 2022). Net loss: US$5.02m (loss narrowed 44% from 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 124 percentage points per year, which is a significant difference in performance. Duyuru • Aug 03
Vericel Corporation Revises Earnings Guidance for the Year 2023 Vericel Corporation revised earnings guidance for the year 2023. Total net revenue for 2023 now expected to be in the range of $190 to $197 million compared to the previous guidance of $184 to $192 million. Duyuru • Jul 23
Vericel Corporation to Report Q2, 2023 Results on Aug 02, 2023 Vericel Corporation announced that they will report Q2, 2023 results on Aug 02, 2023 Duyuru • May 11
Vericel Corporation Raises Revenue Guidance for the Fiscal Year 2023 Vericel Corporation raised revenue guidance for the fiscal year 2023. for the year, the company expects Total net revenue for 2023 now expected to be in the range of $184 to $192 million compared to the previous guidance of $180 to $188 million. Reported Earnings • May 10
First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.15 loss in 1Q 2022) First quarter 2023 results: US$0.16 loss per share (further deteriorated from US$0.15 loss in 1Q 2022). Revenue: US$41.0m (up 14% from 1Q 2022). Net loss: US$7.50m (loss widened 5.7% from 1Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 100 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 24
Full year 2022 earnings released: US$0.35 loss per share (vs US$0.16 loss in FY 2021) Full year 2022 results: US$0.35 loss per share (further deteriorated from US$0.16 loss in FY 2021). Revenue: US$164.4m (up 5.2% from FY 2021). Net loss: US$16.7m (loss widened 124% from FY 2021). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Duyuru • Feb 10
Vericel Corporation to Report Q4, 2022 Results on Feb 23, 2023 Vericel Corporation announced that they will report Q4, 2022 results on Feb 23, 2023 Duyuru • Jan 12
Vericel Corporation Announces Accelerated Launch Timeline for MACI Arthroscopic Program Vericel Corporation announced an accelerated launch timeline for MACI® arthroscopic delivery, which is now anticipated to be launched in 2024. Following a Type C meeting with the FDA, the Company is planning to initiate a human factors validation study to support expanding the MACI label to include arthroscopic administration of MACI for the treatment of cartilage defects of the knee and now anticipates an accelerated potential commercial launch of arthroscopic MACI in 2024 Announced FDA approval of NexoBrid® (anacaulase-bcdb) on December 28, 2022 for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns, with U.S. commercial availability expected in the second quarter of 2023 and Expect to hold a pre-IND meeting with the FDA in the first half of 2023 to discuss the MACI development program for the treatment of cartilage defects in the ankle. Duyuru • Jan 11
Vericel Corporation Provides Revenue Guidance for the Full-Year 2022 Vericel Corporation provided revenue guidance for the full-year 2022. For the year, company expected Total net revenue to be approximately $164 million to $165 million. Duyuru • Dec 31
Vericel Announces Fda Approval of Nexobrid for the Treatment of Severe Thermal Burns in Adults Vericel Corporation announced that the U.S. Food and Drug Administration (FDA) has approved NexoBrid® (anacaulase-bcdb) for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns. The FDA approval of NexoBrid is based on multiple preclinical and clinical studies, including the pivotal Phase 3 U.S. clinical study (DETECT) which evaluated NexoBrid in adult patients with deep partial-thickness and full-thickness thermal burns of 3%-30% of total body surface area (TBSA). The study met its primary endpoint of complete eschar removal as well as all secondary endpoints, including shorter time to eschar removal and a lower incidence of surgical eschar removal compared to standard of care (SOC), including both surgical and non-surgical eschar removal methods. A key safety endpoint, non-inferiority in time to >95% wound closure compared with patients treated with SOC, was also achieved. NexoBrid can be applied in up to two applications of four hours each. A first application of NexoBrid may be applied to an area of up to 15% body surface area. A second application of NexoBrid may be applied 24 hours later, with a total treated area for both applications of up to 20% TBSA. NexoBrid (anacaulase-bcdb) is a botanical drug product containing proteolytic enzymes indicated for the removal of eschar in adults with deep partial- and/or full-thickness thermal burns. Indications for Use: NexoBrid (anacaulase-bcdb) is indicated for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The safety and effectiveness of NexoBrid have not been established for treatment of: Chemical or electrical burns Burns on the face, perineum, or genitalia Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease, Circumferential burns, Burns in patients with significant cardiopulmonary disease, including inhalation injury. Reported Earnings • Nov 10
Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.11 loss in 3Q 2021) Third quarter 2022 results: US$0.14 loss per share (further deteriorated from US$0.11 loss in 3Q 2021). Revenue: US$38.6m (up 12% from 3Q 2021). Net loss: US$6.58m (loss widened 33% from 3Q 2021). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Duyuru • Nov 10
Vericel Corporation Provides Earnings Guidance for the Full-Year 2022 Vericel Corporation provided earnings guidance for the full-Year 2022. For the year, the company expects total net revenue to be in the range of $164 million to $166 million. Duyuru • Oct 27
Vericel Corporation to Report Q3, 2022 Results on Nov 09, 2022 Vericel Corporation announced that they will report Q3, 2022 results on Nov 09, 2022 Reported Earnings • Aug 04
Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.082 loss in 2Q 2021) Second quarter 2022 results: US$0.19 loss per share (down from US$0.082 loss in 2Q 2021). Revenue: US$37.0m (down 6.3% from 2Q 2021). Net loss: US$8.96m (loss widened 137% from 2Q 2021). Over the next year, revenue is forecast to grow 30%, compared to a 31% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Duyuru • Aug 04
Vericel Corporation Announces Revenue Guidance for the Full Year of 2022 Vericel Corporation announced revenue guidance for the full year of 2022. For the year, the company expected Total revenue to be $178 million to $189 million. Duyuru • Jul 22
Vericel Corporation Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America of Patients with Large Posterior Trunk Burns Treated with Epicel Vericel Corporation announced the publication of results from a retrospective study conducted by the Burn and Reconstructive Centers of America (BRCA) of 40 patients with large posterior trunk burns treated with Epicel® (cultured epidermal autografts) in the Journal of Burn Care & Research. Severe burns on posterior trunk surfaces present special consideration since the posterior surfaces bear the major portion of the body weight. The study evaluated the success of engraftment in patients receiving Epicel for posterior trunk burns with total burn surface area (TBSA) =30% treated at three high-volume burn centers within the BRCA between March 2016 and December 2019.The retrospective study consisted of 40 patients with a mean age of 38 years (68% male, 32% female) with burn etiology fire/flame (78%). The mean TBSA was 56% (range 30% to 95%), with a mean revised BAUX Score of 97 (range 49 to 141). The location of the burns on the posterior trunk were ‘back only' (55%), ‘back and buttocks’ (27.5%), and ‘buttocks only' (5%). The median percentage of area covered by burn in all three categories was 100%. Key findings include: 83% (33/40) of patients with posterior burns had successful engraftment after one or two applications of Epicel. 70% (28/40) of patients treated had successful engraftment after one application of Epicel. These patients had younger mean age, lower mean %TBSA, burn location on the posterior trunk of the back only (vs. back and buttocks or buttocks only), and Epicel was applied over split thickness skin graft (STSG). 90% survival rate following one or two applications with Epicel and/or Epicel plus STSG. Of the four patients who died, three were =55 years of age (range 55 to 71 years) with %TBSA =42% (range 42% to 74%), the fourth patient was under 18 with 95% TBSA. The mean revised BAUX Score for these four patients was 122 (range 111 to 129) which is associated with an approximately 67% mortality (33% survival) rate. Epicel® (cultured epidermal autografts) is authorized for use in adult and pediatric patients who have deep dermal or full thickness burns comprising a total body surface area greater than or equal to 30%. It may be used in conjunction with split-thickness autografts, or alone in patients for whom split-thickness autografts may not be an option due to the severity and extent of their burns. The effectiveness of the device for this use has not been demonstrated. Duyuru • Jul 21
Vericel Corporation to Report Q2, 2022 Results on Aug 03, 2022 Vericel Corporation announced that they will report Q2, 2022 results on Aug 03, 2022 Reported Earnings • May 05
First quarter 2022 earnings released: US$0.15 loss per share (vs US$0.072 loss in 1Q 2021) First quarter 2022 results: US$0.15 loss per share (down from US$0.072 loss in 1Q 2021). Revenue: US$36.1m (up 4.4% from 1Q 2021). Net loss: US$7.09m (loss widened 116% from 1Q 2021). Over the next year, revenue is forecast to grow 23%, compared to a 28% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Duyuru • May 05
Vericel Corporation Reaffirms Earnings Guidance for the Year 2022 Vericel Corporation reaffirmed earnings guidance for the year 2022. Total net revenue for 2022 expected to be in the range of $178 to $189 million. Gross margin expected to be approximately 70%. Reported Earnings • Feb 25
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: US$0.16 loss per share (down from US$0.063 profit in FY 2020). Revenue: US$156.2m (up 26% from FY 2020). Net loss: US$7.47m (down 361% from profit in FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 18%, compared to a 61% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Duyuru • Feb 11
Vericel Corporation to Report Q4, 2021 Results on Feb 24, 2022 Vericel Corporation announced that they will report Q4, 2021 results on Feb 24, 2022 Reported Earnings • Nov 10
Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.08 profit in 3Q 2020) The company reported a soft third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$34.5m (up 7.0% from 3Q 2020). Net loss: US$4.93m (down 236% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth. Duyuru • Aug 05
Vericel Corporation Raises Revenue Guidance for the Year 2021 Vericel Corporation raised revenue guidance for the year 2021. For the year, the company expects total net revenue to be in the range of $168 million to $171 million, compared to previous guidance of approximately $165 million to $168 million. Reported Earnings • Aug 05
Second quarter 2021 earnings released: US$0.082 loss per share (vs US$0.18 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$39.5m (up 98% from 2Q 2020). Net loss: US$3.79m (loss narrowed 54% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 58% per year, which means it is significantly lagging earnings growth. Board Change • Jul 31
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 5 highly experienced directors. Independent Director Lisa Wright was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Executive Departure • Jul 06
VP, Principal Accounting Officer & Controller Sandra Pennell has left the company On the 2nd of July, Sandra Pennell's tenure as VP, Principal Accounting Officer & Controller ended after 6.5 years in the role. As of March 2021, Sandra still personally held 3.73k shares (€162k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.96 years, which is considered inexperienced in the Simply Wall St Risk Model. Duyuru • Jun 12
Vericel Corporation Provides Revenue Guidance for the Year 2021 Vericel Corporation provided revenue guidance for the year 2021. For the year, the company expects revenue guidance, of about $165 million to $168 million or 33% to 35% revenue growth for the year. Recent Insider Transactions • May 18
Independent Director recently sold €208k worth of stock On the 14th of May, Paul Wotton sold around 5k shares on-market at roughly €41.63 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • May 06
First quarter 2021 earnings released: US$0.072 loss per share (vs US$0.10 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$34.6m (up 30% from 1Q 2020). Net loss: US$3.29m (loss narrowed 30% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 61% per year, which means it is significantly lagging earnings growth. Duyuru • May 06
Vericel Corporation Provides Earnings Guidance for the Full Year 2021 Vericel Corporation provides earnings guidance for the full year 2021. Total net revenue now expected to be in the range of $165-$168 million, compared to previous guidance of approximately $161-$164 million. Duyuru • Mar 20
Vericel Corporation, Annual General Meeting, Apr 28, 2021 Vericel Corporation, Annual General Meeting, Apr 28, 2021, at 09:00 US Eastern Standard Time. Agenda: To consider election of directors; to consider approve, on an advisory basis, the compensation of company’s named executive officers; and to ratify the appointment of PricewaterhouseCoopers LLP as company’s Independent Registered Public Accounting firm for the fiscal year ending December 31, 2021. Reported Earnings • Feb 25
Full year 2020 earnings released: EPS US$0.063 (vs US$0.22 loss in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$124.2m (up 5.4% from FY 2019). Net income: US$2.86m (up US$12.5m from FY 2019). Profit margin: 2.3% (up from net loss in FY 2019). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has increased by 82% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Feb 25
Revenue beats expectations Revenue exceeded analyst estimates by 0.2%. Over the next year, revenue is forecast to grow 30%, compared to a 52% growth forecast for the Biotechs industry in Germany. Is New 90 Day High Low • Feb 03
New 90-day high: €36.76 The company is up 103% from its price of €18.12 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.062 per share. Duyuru • Jan 26
Vericel Corporation Announces the Appointment of Joseph A. Mara as Chief Financial Officer On January 25, 2021, Vericel Corporation announced the appointment of Joseph A. Mara, as Chief Financial Officer of the company. Mr. Mara will also serve as the company's Principal Financial Officer and Treasurer. Prior to joining the Company, Mr. Mara served as Vice President, Finance and Head of Investor Relations at Biogen Inc. since 2019. Prior to serving in that capacity, since 2007, Mr. Mara served in a variety of roles of increasing responsibility at Biogen, including: Vice President, Global FP&A and Strategic Corporate Finance; Vice President, U.S. Finance and Operations; Senior Director, U.S. Finance; and Director, U.S. Commercial Finance. Is New 90 Day High Low • Jan 07
New 90-day high: €25.44 The company is up 40% from its price of €18.22 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €46.40 per share. Is New 90 Day High Low • Dec 12
New 90-day high: €22.13 The company is up 55% from its price of €14.30 on 11 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €47.75 per share. Is New 90 Day High Low • Nov 07
New 90-day high: €18.88 The company is up 48% from its price of €12.76 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €41.93 per share. Reported Earnings • Nov 07
Third quarter 2020 earnings released: EPS US$0.08 The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2020 results: Revenue: US$32.3m (up 5.8% from 3Q 2019). Net income: US$3.62m (up 4.3% from 3Q 2019). Profit margin: 11% (in line with 3Q 2019). Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has increased by 75% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Nov 07
Revenue beats expectations Revenue exceeded analyst estimates by 4.1%. Over the next year, revenue is forecast to grow 26%, compared to a 312% growth forecast for the Biotechs industry in Germany. Is New 90 Day High Low • Oct 02
New 90-day high: €16.29 The company is up 22% from its price of €13.40 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €40.65 per share. Duyuru • Sep 17
Vericel Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns Vericel Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the recently submitted Biologics License Application (BLA) for NexoBrid® (concentrate of proteolytic enzymes enriched in bromelain) for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of June 29, 2021. In addition, the FDA communicated that it is not currently planning to hold an advisory committee meeting to discuss the application. Duyuru • Jul 23
Vericel Corporation to Report Q2, 2020 Results on Aug 05, 2020 Vericel Corporation announced that they will report Q2, 2020 results at 12:30 PM, GMT Standard Time on Aug 05, 2020 
